1. Seedat S, Stein DJ. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trialInt Clin Psychopharmacol. (1999)
  2. Colazingari S, et al. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trialArch Gynecol Obstet. (2013)
  3. Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patientsEur Rev Med Pharmacol Sci. (2013)
  4. Agostini R, Rossi F, Pajalich R. Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled studyEur Rev Med Pharmacol Sci. (2006)
  5. Michell RH. The multiplying roles of inositol lipids and phosphates in cell control processesEssays Biochem. (1997)
  6. Parthasarathy R, Eisenberg F Jr. The inositol phospholipids: a stereochemical view of biological activityBiochem J. (1986)
  7. Kaiser LG, et al. Scyllo-inositol in normal aging human brain: 1H magnetic resonance spectroscopy study at 4 TeslaNMR Biomed. (2005)
  8. Salloway S, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseNeurology. (2011)
  9. Holub BJ. The nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and diseaseAdv Nutr Res. (1982)
  10. Clements RS Jr, Reynertson R. Myoinositol metabolism in diabetes mellitus. Effect of insulin treatmentDiabetes. (1977)
  11. Clements RS Jr, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol dietAm J Clin Nutr. (1980)
  12. Dang NT, et al. D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 miceBiosci Biotechnol Biochem. (2010)
  13. Balla T. Phosphoinositide-derived messengers in endocrine signalingJ Endocrinol. (2006)
  14. Agranoff BW. Turtles All the Way: Reflections on myo-InositolJ Biol Chem. (2009)
  15. Draskovic P, et al. Inositol hexakisphosphate kinase products contain diphosphate and triphosphate groupsChem Biol. (2008)
  16. Mulugu S, et al. A conserved family of enzymes that phosphorylate inositol hexakisphosphateScience. (2007)
  17. Shears SB. Assessing the omnipotence of inositol hexakisphosphateCell Signal. (2001)
  18. Irvine RF. Inositide evolution – towards turtle dominationJ Physiol. (2005)
  19. Irvine RF, Schell MJ. Back in the water: the return of the inositol phosphatesNat Rev Mol Cell Biol. (2001)
  20. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseasesBiochimie. (2013)
  21. Shaldubina A, et al. Inositol deficiency diet and lithium effectsBipolar Disord. (2006)
  22. Eisenberg F Jr, Parthasarathy R. Measurement of biosynthesis of myo-inositol from glucose 6-phosphateMethods Enzymol. (1987)
  23. Deranieh RM, et al. Probing myo-inositol 1-phosphate synthase with multisubstrate adductsOrg Biomol Chem. (2012)
  24. Asplin I, Galasko G, Larner J. chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjectsProc Natl Acad Sci U S A. (1993)
  25. Kennington AS, et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitusN Engl J Med. (1990)
  26. Scioscia M, et al. Urinary excretion of inositol phosphoglycan P-type in gestational diabetes mellitusDiabet Med. (2007)
  27. Baillargeon JP, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndromeDiabetes Care. (2006)
  28. Baillargeon JP, et al. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolismHum Reprod. (2008)
  29. Stull AJ, et al. Relationships between urinary inositol excretions and whole-body glucose tolerance and skeletal muscle insulin receptor phosphorylationMetabolism. (2008)
  30. Larner J, Craig JW. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistanceDiabetes Care. (1996)
  31. Coady MJ, et al. Identification of a novel Na+/myo-inositol cotransporterJ Biol Chem. (2002)
  32. Ostlund RE Jr, et al. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-{3-3H}inositolJ Biol Chem. (1996)
  33. Gullapalli RP. Soft gelatin capsules (softgels)J Pharm Sci. (2010)
  34. Carlomagno G, et al. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical useExpert Opin Drug Deliv. (2012)
  35.  Gianfranco C, et al. Myo-inositol in the treatment of premenstrual dysphoric disorderHum Psychopharmacol. (2011)
  36. Larner J. D-chiro-inositol–its functional role in insulin action and its deficit in insulin resistanceInt J Exp Diabetes Res. (2002)
  37. Sun TH, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controlsBiochem Biophys Res Commun. (2002)
  38. Yamashita Y, et al. Detection of orally administered inositol stereoisomers in mouse blood plasma and their effects on translocation of glucose transporter 4 in skeletal muscle cellsJ Agric Food Chem. (2013)
  39. Kofman O, et al. Chronic dietary inositol enhances locomotor activity and brain inositol levels in ratsPsychopharmacology (Berl). (1998)
  40. Agam G, et al. High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithiumPharmacol Biochem Behav. (1994)
  41. Patishi Y, et al. Differential uptake of myo-inositol in vivo into rat brain areasEur Neuropsychopharmacol. (1996)
  42. Spector R. Myo-inositol transport through the blood-brain barrierNeurochem Res. (1988)
  43. Kofman O, et al. Restoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizuresPsychopharmacology (Berl). (1993)
  44. Levine J, et al. Inositol treatment raises CSF inositol levelsBrain Res. (1993)
  45. Shimon H, et al. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorderAm J Psychiatry. (1997)
  46. Manji HK, et al. Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositolNeuropsychopharmacology. (1996)
  47. Levine J, et al. Double-blind, controlled trial of inositol treatment of depressionAm J Psychiatry. (1995)
  48. Levine J, et al. Follow-up and relapse analysis of an inositol study of depressionIsr J Psychiatry Relat Sci. (1995)
  49. Gelber D, Levine J, Belmaker RH. Effect of inositol on bulimia nervosa and binge eatingInt J Eat Disord. (2001)
  50. Nemets B, et al. Inositol addition does not improve depression in SSRI treatment failuresJ Neural Transm. (1999)
  51. Levine J, et al. Combination of inositol and serotonin reuptake inhibitors in the treatment of depressionBiol Psychiatry. (1999)
  52. Inositol 6 g daily may be effective in depression but not in schizophrenia.
  53. Zukov I, et al. Premenstrual dysphoric disorder–review of actual findings about mental disorders related to menstrual cycle and possibilities of their therapyPrague Med Rep. (2010)
  54. Nemets B, et al. Myo-inositol has no beneficial effect on premenstrual dysphoric disorderWorld J Biol Psychiatry. (2002)
  55. Chengappa KN, et al. Inositol as an add-on treatment for bipolar depressionBipolar Disord. (2000)
  56. Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepinesJ Psychiatr Res. (2010)
  57. Qureshi NA, Al-Bedah AM. Mood disorders and complementary and alternative medicine: a literature reviewNeuropsychiatr Dis Treat. (2013)
  58. Nierenberg AA, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidoneAm J Psychiatry. (2006)
  59. Cohen H, et al. Inositol has behavioral effects with adaptation after chronic administrationJ Neural Transm. (1997)
  60. Einat H, et al. Chronic epi-inositol has an anxiolytic-like effect in the plus-maze model in ratsInt J Neuropsychopharmacol. (1998)
  61. Kofman O, et al. The anxiolytic effect of chronic inositol depends on the baseline level of anxietyJ Neural Transm. (2000)
  62. Palatnik A, et al. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorderJ Clin Psychopharmacol. (2001)
  63. Benjamin J, et al. Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorderJ Psychiatr Res. (1997)
  64. Benjamin J, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorderAm J Psychiatry. (1995)
  65. Kaplan Z, et al. Inositol treatment of post-traumatic stress disorderAnxiety. (1996)
  66. Levine J, et al. CSF inositol in schizophrenia and high-dose inositol treatment of schizophreniaEur Neuropsychopharmacol. (1994)
  67. Levine J, et al. Lack of effect of inositol treatment in chronic schizophreniaBiol Psychiatry. (1993)
  68. Fux M, et al. Inositol treatment of obsessive-compulsive disorderAm J Psychiatry. (1996)
  69. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression.
  70. Kofman O, et al. The effect of peripheral inositol injection on rat motor activity models of depressionIsr J Med Sci. (1993)
  71. Levine J, et al. Lack of effect of 6 g inositol treatment of post-ECT cognitive function in humansJ Psychiatr Res. (1995)
  72. Michaelis T, et al. Identification of Scyllo-inositol in proton NMR spectra of human brain in vivoNMR Biomed. (1993)
  73. Frahm J, et al. Localized proton NMR spectroscopy of brain tumors using short-echo time STEAM sequencesJ Comput Assist Tomogr. (1991)
  74. Seaquist ER, Gruetter R. Identification of a high concentration of scyllo-inositol in the brain of a healthy human subject using 1H- and 13C-NMRMagn Reson Med. (1998)
  75. Fenili D, et al. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathologyJ Mol Med (Berl). (2007)
  76. McLaurin J, et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicityJ Biol Chem. (2000)
  77. Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathwayJ Neurosci. (2007)
  78. McLaurin J, et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse modelNat Med. (2006)
  79. Townsend M, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomersAnn Neurol. (2006)
  80. Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men.
  81. Barak Y, et al. Inositol treatment of Alzheimer’s disease: a double blind, cross-over placebo controlled trialProg Neuropsychopharmacol Biol Psychiatry. (1996)
  82. Levine J, et al. Inositol treatment of autismJ Neural Transm. (1997)
  83. Brosche T. Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic valuesArch Gerontol Geriatr. (2001)
  84. Maeba R, et al. Plasmalogens in human serum positively correlate with high- density lipoprotein and decrease with agingJ Atheroscler Thromb. (2007)
  85. Bräutigam C, et al. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresisAtherosclerosis. (1996)
  86. Maeba R, Ueta N. Determination of choline and ethanolamine plasmalogens in human plasma by HPLC using radioactive triiodide (1-) ion (125I3-)Anal Biochem. (2004)
  87. Maeba R, et al. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndromeJ Nutr Sci Vitaminol (Tokyo). (2008)
  88. Saltiel AR. Second messengers of insulin actionDiabetes Care. (1990)
  89. Caro HN, et al. Isolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liverBiochem Mol Med. (1997)
  90. McLean P, et al. Reciprocal control of pyruvate dehydrogenase kinase and phosphatase by inositol phosphoglycans. Dynamic state set by „push-pull“ systemJ Biol Chem. (2008)
  91. Roche TE, et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoformsProg Nucleic Acid Res Mol Biol. (2001)
  92. Denton RM, et al. The hormonal regulation of pyruvate dehydrogenase complexAdv Enzyme Regul. (1996)
  93. Harris RA, et al. Regulation of the activity of the pyruvate dehydrogenase complexAdv Enzyme Regul. (2002)
  94. Cohen P. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal LectureEur J Biochem. (2001)
  95. Cohen P. The origins of protein phosphorylationNat Cell Biol. (2002)
  96. Kunjara S, et al. Inositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changesMol Genet Metab. (1999)
  97. Shashkin PN, et al. Insulin mediators in man: effects of glucose ingestion and insulin resistanceDiabetologia. (1997)
  98. Larner J. D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at workIUBMB Life. (2001)
  99. Dugani CB, Klip A. Glucose transporter 4: cycling, compartments and controversiesEMBO Rep. (2005)
  100. Farese RV, Sajan MP, Standaert ML. Atypical protein kinase C in insulin action and insulin resistanceBiochem Soc Trans. (2005)
  101. Ng Y, et al. Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytesCell Metab. (2008)
  102. Randhawa VK, et al. GLUT4 vesicle recruitment and fusion are differentially regulated by Rac, AS160, and Rab8A in muscle cellsJ Biol Chem. (2008)
  103. Ijuin T, Takenawa T. Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP)J Biol Chem. (2012)
  104. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell functionJ Biol Chem. (1999)
  105. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4Nat Rev Mol Cell Biol. (2002)
  106. Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling conceptsJ Neurochem. (2007)
  107. Tanti JF, et al. Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytesJ Biol Chem. (1996)
  108. Kotani K, et al. Requirement for phosphoinositide 3-kinase in insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytesBiochem Biophys Res Commun. (1995)
  109. Kanai F, et al. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinaseBiochem Biophys Res Commun. (1993)
  110. Furuichi T, et al. Intracellular channelsCurr Opin Neurobiol. (1994)
  111. Iwai M, et al. Molecular cloning of mouse type 2 and type 3 inositol 1,4,5-trisphosphate receptors and identification of a novel type 2 receptor splice variantJ Biol Chem. (2005)
  112. Co-expression in vertebrate tissues and cell lines of multiple inositol 1,4,5-trisphosphate (InsP3) receptors with distinct affinities for InsP3.
  113. Nakashima N, et al. The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytesJ Biol Chem. (2000)
  114. Stiles B, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity {corrected}Proc Natl Acad Sci U S A. (2004)
  115. Kurlawalla-Martinez C, et al. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissueMol Cell Biol. (2005)
  116. Wada T, et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activityMol Cell Biol. (2001)
  117. Sasaoka T, et al. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubesDiabetologia. (2001)
  118. Sleeman MW, et al. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesityNat Med. (2005)
  119. Ijuin T, Takenawa T. SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formationMol Cell Biol. (2003)
  120. Ijuin T, et al. Increased insulin action in SKIP heterozygous knockout miceMol Cell Biol. (2008)
  121. Kong AM, et al. Phosphatidylinositol 3-phosphate {PtdIns3P} is generated at the plasma membrane by an inositol polyphosphate 5-phosphatase: endogenous PtdIns3P can promote GLUT4 translocation to the plasma membraneMol Cell Biol. (2006)
  122. Taguchi A, et al. Identification of Glypican3 as a novel GLUT4-binding proteinBiochem Biophys Res Commun. (2008)
  123. Kawa JM, Taylor CG, Przybylski R. Buckwheat concentrate reduces serum glucose in streptozotocin-diabetic ratsJ Agric Food Chem. (2003)
  124. Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitolBr J Pharmacol. (2000)
  125. Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives.
  126. Giordano D, et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled studyMenopause. (2011)
  127. Santamaria A, et al. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndromeClimacteric. (2012)
  128. Corrado F, et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetesDiabet Med. (2011)
  129. D’Anna R, et al. Myo-inositol may prevent gestational diabetes in PCOS womenGynecol Endocrinol. (2012)
  130. Chau JF, et al. Sodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nervesFASEB J. (2005)
  131. Grant PS, Lipscomb D. How often do we ask about erectile dysfunction in the diabetes review clinic? Development of a neuropathy screening toolActa Diabetol. (2009)
  132. Hecht MJ, et al. Neuropathy is a major contributing factor to diabetic erectile dysfunctionNeurol Res. (2001)
  133. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trialEur Rev Med Pharmacol Sci. (2003)
  134. Genazzani AD, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patientsGynecol Endocrinol. (2012)
  135. Donà G, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndromeEur J Endocrinol. (2012)
  136. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation aloneEur Rev Med Pharmacol Sci. (2012)
  137. Gerli S, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOSEur Rev Med Pharmacol Sci. (2007)
  138. Carmina E. PCOS: metabolic impact and long-term managementMinerva Ginecol. (2012)
  139. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysisHippokratia. (2009)
  140. Broekmans FJ, et al. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factorsBJOG. (2006)
  141. Stankiewicz M, Norman R. Diagnosis and management of polycystic ovary syndrome: a practical guideDrugs. (2006)
  142. Cascella T, et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndromeHum Reprod. (2008)
  143. Ciampelli M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndromeMetabolism. (1999)
  144. Metformin in polycystic ovary syndrome: systematic review and meta-analysis.
  145. Unfer V, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trialsGynecol Endocrinol. (2012)
  146. Artini PG, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized studyGynecol Endocrinol. (2013)
  147. Costantino D, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trialEur Rev Med Pharmacol Sci. (2009)
  148. Genazzani AD, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndromeGynecol Endocrinol. (2008)
  149. Papaleo E, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation inductionGynecol Endocrinol. (2007)
  150. Ciotta L, et al. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trialEur Rev Med Pharmacol Sci. (2011)
  151. Lisi F, et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot studyReprod Biol Endocrinol. (2012)
  152. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS womenGynecol Endocrinol. (2010)
  153. Hazell AS, Butterworth RF. Hepatic encephalopathy: An update of pathophysiologic mechanismsProc Soc Exp Biol Med. (1999)
  154. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathyJ Cereb Blood Flow Metab. (1991)
  155. Shawcross DL, et al. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemiaAm J Physiol Gastrointest Liver Physiol. (2004)
  156. Lien YH, et al. Scyllo-inositol depletion in hepatic encephalopathyLife Sci. (1994)
  157. Binesh N, et al. Hepatic encephalopathy: a neurochemical, neuroanatomical, and neuropsychological studyJ Appl Clin Med Phys. (2006)
  158. Wattenberg LW, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositolCarcinogenesis. (2000)
  159. Hecht SS, et al. Dose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzoCancer Lett. (2001)
  160. Estensen RD, Wattenberg LW. Studies of chemopreventive effects of myo-inositol on benzo{a}pyrene-induced neoplasia of the lung and forestomach of female A/J miceCarcinogenesis. (1993)
  161. Lam S, et al. A phase I study of myo-inositol for lung cancer chemopreventionCancer Epidemiol Biomarkers Prev. (2006)
  162. Zacchè MM, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndromeGynecol Endocrinol. (2009)
  163. Skoven I, Thormann J. Lithium compound treatment and psoriasisArch Dermatol. (1979)
  164. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and managementAm J Clin Dermatol. (2000)
  165. Williams RS, et al. A common mechanism of action for three mood-stabilizing drugsNature. (2002)
  166. The effect of inositol on lithium-induced polyuria—polydipsia in rats and humans.
  167. Allan SJ, et al. The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trialBr J Dermatol. (2004)
  168. Cupisti S, et al. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOSExp Clin Endocrinol Diabetes. (2007)
  169. Mueller A, et al. Endocrinological markers for assessment of hyperandrogenemia in hirsute womenHorm Res. (2007)
  170. Minozzi M, D’Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical studyReprod Biomed Online. (2008)
  171. Smith DF. Lithium orotate, carbonate and chloride: pharmacokinetics, polyuria in ratsBr J Pharmacol. (1976)
  172. Minozzi M, et al. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndromeGynecol Endocrinol. (2011)
  173. Galletta M, et al. Bye-bye chiro-inositol – myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation inductionEur Rev Med Pharmacol Sci. (2011)
  174. Isabella R, Raffone E. Does ovary need D-chiro-inositolJ Ovarian Res. (2012)
  175. Tantivejkul K, Vucenik I, Shamsuddin AM. Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: II. Effects on integrins and focal adhesionsAnticancer Res. (2003)
  176. Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer agentLife Sci. (1997)
  177. Singh RP, et al. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factorClin Cancer Res. (2004)
  178. Bohn T, et al. Phytic acid added to white-wheat bread inhibits fractional apparent magnesium absorption in humansAm J Clin Nutr. (2004)
  179. Larsson M, et al. Improved zinc and iron absorption from breakfast meals containing malted oats with reduced phytate contentBr J Nutr. (1996)
  180. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinicJ Nutr. (2003)
  181. Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositolNutr Cancer. (2006)
  182. Tantivejkul K, et al. Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancerBreast Cancer Res Treat. (2003)
  183. Bacić I, et al. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical studyJ Exp Clin Cancer Res. (2010)
  184. Unfer V, et al. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort studyGynecol Endocrinol. (2011)
  185. Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trialEur Rev Med Pharmacol Sci. (2010)
  186. Carlomagno G, Unfer V. Inositol safety: clinical evidencesEur Rev Med Pharmacol Sci. (2011)
  187. Unfer V, et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trialEur Rev Med Pharmacol Sci. (2011)
  188. Iuorno MJ, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndromeEndocr Pract. (2002)
  189. Papaleo E, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trialFertil Steril. (2009)